These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2926064)

  • 1. Acute effect of disopyramide on atrial fibrillation in the Wolff-Parkinson-White syndrome.
    Fujimura O; Klein GJ; Sharma AD; Yee R; Szabo T
    J Am Coll Cardiol; 1989 Apr; 13(5):1133-7. PubMed ID: 2926064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrophysiologic effects of disopyramide phosphate in patients with Wolff-Parkinson-White syndrome.
    Kerr CR; Prystowsky EN; Smith WM; Cook L; Gallagher JJ
    Circulation; 1982 May; 65(5):869-78. PubMed ID: 6804107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disopyramide in patients with the Wolff-Parkinson-White syndrome and atrial fibrillation.
    Bennett DH
    Chest; 1978 Dec; 74(6):624-8. PubMed ID: 738119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the ventricular response during atrial fibrillation in patients with enhanced atrioventricular node conduction and Wolff-Parkinson-White syndrome.
    Milstein S; Klein GJ; Rattes MF; Sharma AD; Yee R
    J Am Coll Cardiol; 1987 Dec; 10(6):1244-8. PubMed ID: 3680792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity and specificity of invasive and noninvasive testing for risk of sudden death in Wolff-Parkinson-White syndrome.
    Sharma AD; Yee R; Guiraudon G; Klein GJ
    J Am Coll Cardiol; 1987 Aug; 10(2):373-81. PubMed ID: 3598007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-excited RR intervals during atrial fibrillation in the Wolff-Parkinson-White syndrome: influence of the atrioventricular node refractory period.
    Fujimura O; Kuo CS; Smith BA
    J Am Coll Cardiol; 1991 Dec; 18(7):1722-6. PubMed ID: 1960320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of disopyramide on electrophysiological properties of specialized conduction system in man and on accessory atrioventricular pathway in Wolff-Parkinson-White syndrome.
    Spurrell RA; Thorburn CW; Camm J; Sowton E; Deuchar DC
    Br Heart J; 1975 Aug; 37(8):861-7. PubMed ID: 53057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of flestolol on ventricular rate during atrial fibrillation in Wolff-Parkinson-White syndrome.
    Swerdlow CD; Peterson J; Liem LB
    Am J Cardiol; 1988 Jul; 62(1):78-82. PubMed ID: 2898208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length.
    Boahene KA; Klein GJ; Yee R; Sharma AD; Fujimura O
    J Am Coll Cardiol; 1990 Nov; 16(6):1408-14. PubMed ID: 2229793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a combination of disopyramide and mexiletine on the anterograde accessory pathway conduction in patients with Wolff-Parkinson-White syndrome.
    Shimizu W; Ohe T; Kurita T; Takaki H; Aihara N; Kamakura S; Matsuhisa M; Shimomura K
    Eur Heart J; 1992 Feb; 13(2):261-8. PubMed ID: 1555626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atrial fibrillation in patients with Wolff-Parkinson-White syndrome: incidence after surgical ablation of the accessory pathway.
    Sharma AD; Klein GJ; Guiraudon GM; Milstein S
    Circulation; 1985 Jul; 72(1):161-9. PubMed ID: 4006127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Electrophysiological action of disopyramide].
    Grosu AA; Malakhov VI; Smetnev AS
    Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR; 1982; 5(2):51-5. PubMed ID: 7138657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of atrial fibrillation and atrioventricular conduction (including Wolff-Parkinson-White syndrome) in sudden death.
    Meijler FL; van der Tweel I; Herbschleb JN; Hauer RN; Robles de Medina EO
    J Am Coll Cardiol; 1985 Jun; 5(6 Suppl):17B-22B. PubMed ID: 3998333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of isoproterenol during atrial fibrillation in evaluation of asymptomatic Wolff-Parkinson-White pattern.
    Szabo TS; Klein GJ; Sharma AD; Yee R; Milstein S
    Am J Cardiol; 1989 Jan; 63(3):187-92. PubMed ID: 2909998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrophysiologic effects of lorcainide on the accessory pathway in the Wolff-Parkinson-White syndrome.
    Kasper W; Treese N; Meinertz T; Jähnchen E; Pop T
    Am J Cardiol; 1983 Jun; 51(10):1618-22. PubMed ID: 6858867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous administration of diltiazem in the treatment of supraventricular tachyarrhythmias.
    Boudonas G; Lefkos N; Efthymiadis AP; Styliadis IG; Tsapas G
    Acta Cardiol; 1995; 50(2):125-34. PubMed ID: 7610735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of intravenous disopyramide phosphate on recurrent paroxysmal tachycardias.
    Camm J; Ward D; Spurrell RA
    Br J Clin Pharmacol; 1979 Nov; 8(5):441-9. PubMed ID: 508548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of flecainide acetate in rapid atrial fibrillation complicating Wolff-Parkinson-White syndrome.
    Kappenberger LJ; Fromer MA; Shenasa M; Gloor HO
    Clin Cardiol; 1985 Jun; 8(6):321-6. PubMed ID: 4006340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Electrophysiological properties of atrial fibrillation with WPW syndrome and the role of procainamide in conversion].
    Li P
    Zhonghua Xin Xue Guan Bing Za Zhi; 1991 Apr; 19(2):65-6, 123. PubMed ID: 1879311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility to atrial fibrillation and ventricular tachyarrhythmia in the Wolff-Parkinson-White syndrome: role of the accessory pathway.
    Waspe LE; Brodman R; Kim SG; Fisher JD
    Am Heart J; 1986 Dec; 112(6):1141-52. PubMed ID: 3788760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.